IL116772A - Sugar coating with microcrystalline cellulose for controlled release of steroids - Google Patents

Sugar coating with microcrystalline cellulose for controlled release of steroids

Info

Publication number
IL116772A
IL116772A IL11677296A IL11677296A IL116772A IL 116772 A IL116772 A IL 116772A IL 11677296 A IL11677296 A IL 11677296A IL 11677296 A IL11677296 A IL 11677296A IL 116772 A IL116772 A IL 116772A
Authority
IL
Israel
Prior art keywords
microcrystalline cellulose
steroids
sugar coating
controlled release
sugar
Prior art date
Application number
IL11677296A
Other languages
English (en)
Other versions
IL116772A0 (en
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23473354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL116772(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Home Prod filed Critical American Home Prod
Publication of IL116772A0 publication Critical patent/IL116772A0/xx
Publication of IL116772A publication Critical patent/IL116772A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL11677296A 1995-01-17 1996-01-16 Sugar coating with microcrystalline cellulose for controlled release of steroids IL116772A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/373,667 US5547948A (en) 1995-01-17 1995-01-17 Controlled release of steroids from sugar coatings

Publications (2)

Publication Number Publication Date
IL116772A0 IL116772A0 (en) 1996-05-14
IL116772A true IL116772A (en) 1999-08-17

Family

ID=23473354

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11677296A IL116772A (en) 1995-01-17 1996-01-16 Sugar coating with microcrystalline cellulose for controlled release of steroids

Country Status (35)

Country Link
US (2) US5547948A (id)
EP (1) EP0722720B1 (id)
JP (1) JP3833292B2 (id)
KR (1) KR100338581B1 (id)
CN (1) CN1106839C (id)
AR (1) AR002019A1 (id)
AT (1) ATE185482T1 (id)
AU (1) AU705879B2 (id)
BR (1) BR9600100B1 (id)
CA (1) CA2167254A1 (id)
CO (1) CO4370096A1 (id)
CZ (1) CZ286102B6 (id)
DE (1) DE69604600T2 (id)
DK (1) DK0722720T3 (id)
EE (1) EE03802B1 (id)
EG (1) EG23687A (id)
ES (1) ES2137627T3 (id)
FI (1) FI117592B (id)
GR (1) GR3031920T3 (id)
HK (1) HK1009935A1 (id)
HU (1) HU223781B1 (id)
ID (1) ID23996A (id)
IL (1) IL116772A (id)
IS (1) IS1878B (id)
MY (1) MY115786A (id)
NO (1) NO315307B1 (id)
NZ (1) NZ280826A (id)
PL (1) PL183330B1 (id)
RU (1) RU2152207C1 (id)
SI (1) SI0722720T1 (id)
SK (1) SK280484B6 (id)
TR (1) TR199600038A2 (id)
TW (1) TW460301B (id)
UA (1) UA37236C2 (id)
ZA (1) ZA96301B (id)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759577A (en) * 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US6451778B1 (en) * 1996-07-26 2002-09-17 Wyeth Oral contraceptive
US6479475B1 (en) * 1996-07-26 2002-11-12 Wyeth Oral contraceptive
CA2230748C (en) * 1997-03-14 2010-08-03 American Home Products Corporation Rapamycin formulations for oral administration
DE19715594A1 (de) 1997-04-15 1998-10-22 Bayer Ag Analgetika-Kombination
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
ATE283687T1 (de) * 1997-06-13 2004-12-15 Wyeth Corp Rapamycin-formulierungen zur oralen verabreichung
US5997905A (en) * 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6432448B1 (en) * 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
AT500063A1 (de) 1999-11-23 2005-10-15 Sandoz Ag Beschichtete tablettenkerne
FR2801218B1 (fr) * 1999-11-23 2001-12-28 Hoechst Marion Roussel Inc Compositions pharmaceutiques comprenant de la trimegestone, leurs procedes de preparation ainsi que le conditionnement primaire les renfermant
US6855703B1 (en) 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
US7989436B2 (en) * 2003-07-23 2011-08-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and pharmaceutical formulations comprising the same
US6660726B2 (en) 2000-03-10 2003-12-09 Endeavor Pharmaceuticals Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
US7459445B2 (en) * 2000-03-10 2008-12-02 Duramed Pharmaceuticals, Inc. Estrogenic compounds and topical pharmaceutical formulations of the same
US20010034340A1 (en) * 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
IL155959A0 (en) 2000-11-28 2003-12-23 Fmc Corp Edible pga (propylene glycol alginate) coating composition
US6630166B1 (en) * 2001-02-12 2003-10-07 Watson Pharmaceuticals, Inc. Compositions for conjugated estrogens and associated methods
US7303763B2 (en) * 2001-02-12 2007-12-04 Watson Laboratories, Inc. Compositions for conjugated estrogens and associated methods
EA200301022A1 (ru) * 2001-03-16 2004-02-26 Уайт Гормональная заместительная терапия
PL364675A1 (en) * 2001-03-16 2004-12-13 Wyeth Estrogen replacement therapy
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
TW200306846A (en) * 2002-04-03 2003-12-01 Wyeth Corp Hormone replacement therapy
TW200306196A (en) * 2002-04-03 2003-11-16 Wyeth Corp Hormone replacement therapy
TW200306851A (en) * 2002-04-29 2003-12-01 Wyeth Corp Hormone replacement therapy
TW200400040A (en) * 2002-05-17 2004-01-01 Wyeth Corp Hormone replacement therapy
US6992075B2 (en) * 2003-04-04 2006-01-31 Barr Laboratories, Inc. C(14) estrogenic compounds
EP1622623A4 (en) * 2003-04-11 2009-03-18 Barr Lab Inc METHOD FOR THE ADMINISTRATION OF ESTROGENIC AND TESTED
AU2004275470B2 (en) * 2003-09-29 2010-12-02 Novo Nordisk Health Care Ag Improved stability of progestogen formulations
GT200500141A (es) * 2004-06-07 2006-01-10 Recubrimiento de azucar y metodos para la fabricacion de los mismos.
CA2580117A1 (en) * 2004-09-23 2006-03-30 Fmc Corporation Coating composition
CA2601773A1 (en) * 2005-02-03 2006-08-10 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
JP2008545012A (ja) * 2005-06-29 2008-12-11 ワイス 結合型エストロゲンおよびバゼドキシフェンの医薬処方
MX2009004960A (es) * 2006-11-07 2009-06-05 Wyeth Corp Revestimientos de azucar y metodos para los mismos.
RU2009117201A (ru) * 2006-11-29 2011-01-10 Вайет (Us) Двухслойные таблетки на основе эстрогена/селективного модулятора эстрогенового рецептора и эстрогена/прогестина
WO2012120365A1 (en) 2011-03-07 2012-09-13 Aurobindo Pharma Limited Stable pharmaceutical composition comprising ethinyl estradiol
AU2012256501B2 (en) * 2011-05-13 2017-04-06 Eb Ip Hybritabs B.V. Drug delivery system
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN105143425B (zh) * 2013-03-15 2019-04-09 蒙诺苏尔有限公司 用于延迟释放的水溶性膜
US10808210B2 (en) 2013-03-15 2020-10-20 Monosol, Llc Water-soluble film for delayed release
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． ステロイドホルモン薬学的組成物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB844772A (en) * 1956-04-19 1960-08-17 Pfizer & Co C Granular pharmaceutical compositions and process for preparing same
GB888631A (en) * 1959-02-24 1962-01-31 Upjohn Co Improvements in or relating to oral therapeutic compositions comprising steroids
FR1396710A (fr) * 1964-06-15 1965-04-23 Diwag Chemische Fabriken G M B Procédé pour la fabrication de charges ou supports perfectionnés et produits obtenus
US3980766A (en) * 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US4154820A (en) * 1976-02-23 1979-05-15 Akzona Incorporated Compositions containing alkali metal sulfate salts of conjugated estrogens and antioxidants as stabilizers
US4248856A (en) * 1979-07-10 1981-02-03 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309405A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4327076A (en) * 1980-11-17 1982-04-27 Life Savers, Inc. Compressed chewable antacid tablet and method for forming same
US4425339A (en) * 1981-04-09 1984-01-10 Syntex (U.S.A.) Inc. Treatment of menopausal symptoms
US4415546A (en) * 1981-05-12 1983-11-15 Janakiraman Ramachandran Biologically active analogs of ACTH and radioimmuno assay therefor
US4390531A (en) * 1981-08-10 1983-06-28 Syntex Pharmaceuticals International Ltd. Method of contraception using peak progestogen dosage
US4415547A (en) * 1982-06-14 1983-11-15 Sterling Drug Inc. Sustained-release pharmaceutical tablet and process for preparation thereof
JPS604120A (ja) * 1983-06-22 1985-01-10 Shionogi & Co Ltd 作用持続型ピナシジル製剤
US4826831A (en) * 1983-08-05 1989-05-02 Pre Jay Holdings Limited Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
GB8403360D0 (en) * 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
DE3586600T2 (de) * 1984-02-10 1993-02-18 Benzon Pharma As Dosierungsform eine vielzahl mit einer diffusionshuelle ueberzogener einheiten enthaltend.
GB8414221D0 (en) * 1984-06-04 1984-07-11 Sterwin Ag Unit dosage form
SE8404467D0 (sv) * 1984-09-06 1984-09-06 Ferrosan Ab Controlled-release medical preparations
US4755386A (en) * 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5208225A (en) * 1986-02-27 1993-05-04 Warner-Lambert Company Compositions containing fixed combinations
GB8705083D0 (en) * 1987-03-04 1987-04-08 Euro Celtique Sa Spheroids
US4927816A (en) * 1987-08-20 1990-05-22 Ester George C Formulae and methods for sublingual ingestion of natural progesterone
US5108995A (en) * 1987-09-24 1992-04-28 Jencap Research Ltd. Hormone preparation and method
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
JP2542122B2 (ja) * 1990-04-18 1996-10-09 旭化成工業株式会社 球状核、球形顆粒およびその製造方法
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5223268A (en) * 1991-05-16 1993-06-29 Sterling Drug, Inc. Low solubility drug-coated bead compositions
NZ262562A (en) * 1993-02-23 1996-04-26 Warner Lambert Co Preparation of solvent free pharmaceutical compositions
ZA949929B (en) * 1993-12-23 1995-08-23 Akzo Nobel Nv Sugar-coated pharmaceutical dosage unit.
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings

Also Published As

Publication number Publication date
FI117592B (fi) 2006-12-15
CN1141168A (zh) 1997-01-29
AU4098296A (en) 1996-07-25
GR3031920T3 (en) 2000-03-31
HUP9600090A3 (en) 1997-05-28
CA2167254A1 (en) 1996-07-18
HK1009935A1 (en) 1999-06-11
CN1106839C (zh) 2003-04-30
NO960191D0 (no) 1996-01-16
RU2152207C1 (ru) 2000-07-10
SK280484B6 (sk) 2000-02-14
TW460301B (en) 2001-10-21
CZ12896A3 (en) 1996-08-14
PL183330B1 (pl) 2002-06-28
EP0722720A1 (en) 1996-07-24
ZA96301B (en) 1997-07-15
DK0722720T3 (da) 2000-01-03
BR9600100B1 (pt) 2009-01-13
UA37236C2 (uk) 2001-05-15
US5547948A (en) 1996-08-20
AR002019A1 (es) 1998-01-07
EG23687A (en) 2007-05-13
FI960210A0 (fi) 1996-01-16
IS4318A (is) 1996-07-18
IL116772A0 (en) 1996-05-14
FI960210A (fi) 1996-07-18
IS1878B (is) 2003-06-20
JPH08231436A (ja) 1996-09-10
SK4996A3 (en) 1997-04-09
KR960028919A (ko) 1996-08-17
DE69604600D1 (de) 1999-11-18
SI0722720T1 (en) 1999-12-31
EE03802B1 (et) 2002-08-15
NO315307B1 (no) 2003-08-18
TR199600038A2 (tr) 1996-08-21
NZ280826A (en) 1996-12-20
MY115786A (en) 2003-09-30
ID23996A (id) 1996-07-25
CO4370096A1 (es) 1996-10-07
EP0722720B1 (en) 1999-10-13
DE69604600T2 (de) 2000-02-24
AU705879B2 (en) 1999-06-03
HUP9600090A2 (en) 1996-12-30
PL312336A1 (en) 1996-07-22
US5759576A (en) 1998-06-02
BR9600100A (pt) 1998-01-27
ES2137627T3 (es) 1999-12-16
HU223781B1 (hu) 2005-01-28
EE9600002A (et) 1996-08-15
NO960191L (no) 1996-07-18
ATE185482T1 (de) 1999-10-15
CZ286102B6 (cs) 2000-01-12
KR100338581B1 (ko) 2002-11-23
JP3833292B2 (ja) 2006-10-11

Similar Documents

Publication Publication Date Title
IL116772A (en) Sugar coating with microcrystalline cellulose for controlled release of steroids
MY115223A (en) Controlled release of steroids from sugar coatings
PL324552A1 (en) Plaster for pecutaneous administration of hormones
TR199800560T1 (xx) Hormon ikamesi tedavisi y�ntemini uygulamaya adapte edilmi� hormon da��t�c�s�.
NZ236031A (en) Osmotic oral contraceptive dosage form, initial dosage of progesterone and estrogen contained in the coat, and prolonged delivery of estrogen from the compartment; fertility controlling program
UA29476C2 (uk) Трансдермальна терапевтична система, що містить естрадіол
WO2001043749A3 (en) Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
BG100940A (en) Combined hormonal contraception pharmaceutical preparation
EP0765663A3 (de) Verwendung von Dienogest zur Herstellung eines Arzneimittels zur Behandlung der Haut mittels topischer Anwendung
EP0888775A3 (en) Control of selective estrogen receptor modulators
AU6367496A (en) New hormonal medicaments and their use for the correction of oestrogenic deficiencies
MX9705806A (es) Forma farmaceutica destinada a la cesion de colagenasa en heridas, y procedimiento para su elaboracion.
ECSP961635A (es) Desprendimiento controlado de esteroides del recubrimiento de azucar
TH30744B (th) " การปลดปล่อยที่ถูกควบคุมของสเตอรอยจากสารเคลือบของน้ำตาล "
GEP19991588B (en) Medicinal Tablet
SG33663A1 (en) Novel sugar coating composition for application to compressed medicinal tablets

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
HCA Change of name of proprietor(s) after amalgamation
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired